Purchase allows company to provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry.
Sharp, a provider of commercial pharmaceutical packaging and clinical trial supply services, has acquired Berkshire Sterile Manufacturing (BSM), a fill-finish contract development and manufacturing organization (CDMO) for clinical and commercial sterile injectable products.
The acquisition enables Sharp to now provide a fully integrated small-to-medium scale sterile injectable service offering for the biopharma industry; the company’s existing clinical supply, packaging, and distribution solutions are expected to complement BSM’s sterile manufacturing knowledge.
“The market continues to demand expertise and capacity in sterile manufacturing due in part to the growth in rare and orphan disease therapies,” says Kevin Orfan, Sharp’s president and CEO. “With sterile injectables a huge part of addressing this unmet medical need, the acquisition of BSM allows Sharp to provide a fully integrated solution for our biopharma clients that is a natural extension of our existing injectables and clinical packaging expertise.”
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
485 Route 1 South,
Building F, Suite 210
Iselin, NJ 08830